Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies

Next Previous
X
Search
Trial Profile

An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VIP 943 (Primary)
  • Indications Acute myeloid leukaemia; B-cell leukaemia; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Vincerx Pharma

    • Most Recent Events

    • 04 Dec 2024 According to a Vincerx media release, company plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, developed with the Company's next-generation VersAptx platform.
    • 12 Nov 2024 According to a Vincerx media release, company expects to share additional Phase 1 study data for VIP943 by early 2025. Company continues dose escalation to assess potential for additional efficacy. Enrollment in the once-weekly and twice-weekly (as an induction therapy) dosing schedules is ongoing.
    • 07 Oct 2024 According to a Vincerx media release, company anticipates providing another data update on the ongoing Phase 1 VIP943 study by the end of the year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top